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Myelin basic protein serves as a convenient substrate for detection of a 44 kDa protein-serine/threonine kinase (p44”“L) that is activated near the 
time of germinal vesicle breakdown in maturing echinoderm and amphibian oocytes. In vitro phosphorylation by purified p44”“L from sea star 
oocytes was primarily on threonine residues on a single tryptic peptide of bovine brain myelin basic protein. Amino acid composition analysis 
of the isolated posphopcptide revealed that it was rich in proline residues. Automated solid-phase sequencing by Edman degradation identified 
the major site as Thr-97 in the sequence NIVTPRTPPPSQGK, which corresponds to residues 91-104 in bovine brain myelin basic protein. Thr-94 
was also phosphorylated by p44~~ to a very minor extent. 
Myelin basic protein kinase; MAP-2 kinase; Meiosis 
1. INTRODUCTION 
Abundant cellular proteins can be useful probes for 
the detection of protein kinases for which the 
physiological substrates are unknown (see [l] for 
review). We have found that bovine brain myelin basic 
protein (MBP) serves as an efficient substrate for a 44 
kDa protein-serine/threonine kinase that is activated 
near the time of nuclear envelope breakdown in 
1-methyladenine-treated sea star oocytes [2] as well as 
Xenopus faevis oocytes induced to mature with pro- 
gesterone [3]. This sea star kinase, provisionally 
designated p44”@, has been purified to homogeneity 
from maturing oocytes and shown to have a restricted 
specificity [4]. Microprotein sequencing of tryptic pep- 
tides derived from the purified kinase has indicated that 
it is a novel protein kinase (R.A., J.S. and S.P., un- 
published). However, p44”@ shares many character- 
istics with a murine 42 kDa mitogen-activated protein 
kinase (~42~~9 that phosphorylates microtubule- 
associated protein MAP-2 [5,6]. 
of the two kinases are correlated to their phosphoryla- 
tion by unknown protein-tyrosine kinases, and both 
kinases, in turn, can phosphorylate homologous 90-92 
kDa ribosomal protein S6 kinases [7,8] (J.S. and S.P., 
unpublished). It has been proposed that ~42~~ is the 
42 kDa phosphoprotein that undergoes tyrosine 
phosphorylation in a variety of mammalian and avian 
cells in response to polypeptide mitogens and phorbol 
ester tumor promoters, based upon their co-elution 
from different types of chromatography columns [9]. 
Recently, we have observed that rabbit polyclonal an- 
tibodies generated against ~44~~~ purified from sea star 
oocytes immunoreacts with murine ~42~~, further 
supporting the relatedness of these kinases (T. Sturgill, 
J.S. and S.P., unpublished). To begin to delineate the 
consensus phosphorylation site sequences in substrates 
that are recognized by ~44”~~, we have characterized 
the sites that are phosphorylated by this kinase in MBP 
using high sensitivity solid-phase sequence analysis. 
The protein kinases p44mpk and ~42~~ both appear 
to operate in protein kinase cascades, albeit at different 
points in the cell cycle; ~44~~’ is active at M-phase and 
~42~~~ during the GO to Gt transition. The activations 
2. MATERIALS AND METHODS 
2.1. Materials 
The protein kinase ~44”~~ was isolated from maturing Pisaster 
ochraceus oocytes [4]. Bovine brain MBP, phosphoamino acid 
standards, and trypsin (type IX, porcine pancreas) were purchased 
from Sigma. [y-“P]ATP was from ICN. 
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2.2. Phosphorylation of MBP 
Abbreviations: cdc-2 kinase, protein kinase encoded by homologs of 
the S. pombe cell division control-2 gene; MBP, myelin basic protein; 
~42~‘, mitogen-activated microtubule-associated protein-2 kinase; 
p44mp”, meiosis-activated MBP kinase; TFA, trifluoroacetic acid 
The phosphorylation of MBP by ~44~~~ was performed at 30°C for 
30 min. The reaction mixture contained in a final volume of 50 ~1: 1 
mg/ml MBP, 2 pgg/ml p44mpk, 50 fl [T’~P]ATP (2000 cpm/pmol), 
30 mM &glycerophosphate. 20 mM Mops (pH 7.2), 20 mM MgCh, 
5 mM EGTA. 1 mM dithiothreitol and 0.5 mM sodium vanadate. The 
reaction was terminated by addition of 10 volumes of cold acetone 
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( - 2O’C) and incubation on ice for 30 min. The phosphorylated MBP 
was pelleted by centrifugation in a microfuge for 5 min. 
2.3. Trypsin digestion and fractionation of peptides 
Phosphorylated MBP was resuspended in 10 ~1 of 0.5 M NaHCOs, 
8 M urea (pH 8.2). The concentration of urea was lowered to 2 M by 
the addition of 30 ~1 HzO. Trypsin (2 $1 of 1 mg/ml) was added and 
the incubation performed at 37°C overnight. The resulting peptides 
were separated by narrow-bore reverse phase high performance liquid 
chromatography (column, Vydac C-4,2.1 x 150 mm) using a Waters 
peptide analyzer. Prior to application to the column, 10 ~1 of 
trifluoroacetic acid (TFA):HzO (10:90, v/v) were added to the mix- 
ture of peptides. Chromatography solvents were: solvent A, 0.01% 
TFA in H20; and solvent B, O.OS-0.095% TFA in HzO:acetonitrile 
(30:70, v/v). UV absorption of the solvents was matched at 215 nm 
by titrating the TFA concentration in solvent B. Peptides were eluted 
with a O-70% acetonitrile gradient, monitored by UV absorption at 
215 nm, and collected manually for further analysis. Peptides co- 
eluting from this initial separation were further resolved using condi- 
tions of different chromatographic selectivity (column, Vydac C-18, 
2.1 X 150 mm; solvent A, 150 mM NaCl in H20; solvent B, 
acetonitrile:HzO (30:30, v/v). 
Two-dimensional peptide mapping of “2P-labelled peptides was 
performed with trypsin-digested MBP and HPLC-isolated peptides. 
The samples were vacuum dried in a Speedy Vat system, resuspended 
in 5 ~1 electrophoresis buffer (1% ammonium bicarbonate, pH 8.9) 
and spotted on to a cellulose TLC plate (Merck). Electrophoresis in 
the first dimension was at 600 V for 40 min. The plate was dried and 
developed in the second dimension in butanol:pyridine:acetic 
acid:HzO (32.5:25:5:20, v/v/v/v). The TLC plate was dried and ex- 
posed to film (Kodak, XAR-5) for autoradiography. 
2.4. Amino acid composition analysis, phosphoamino acid analysis 
and amino acid sequencing 
Phosphoamino acid analysis was performed by hydrolyzing a small 
amount of prelabelled peptide with 200 11 of constant boiling HCI 
(Pierce) for 1 h at 105°C. The HCl was vacuum dried in a Speedy Vat 
system, and the amino acids resuspended in 100 pl of HzO. The sam- 
ple was dried again and resuspended in 5 ~1 of electrophoresis buffer 
(HzO:acetic acid:pyridine (945:50:5, v/v/v)) containing 1 mg/ml each 
of phosphoserine, phosphothreonine and phosphotyrosine. After 
spotting the samples on to silica TCL plates, electrophoresis was per- 
formed for 60 min at 1000 V with a constant cooling flatbed elec- 
trophoresis apparatus. Standards were visualized by ninhydrin and 
autoradiography was performed on the TLC plate. 
Amino acid composition analysis of totally hydrolyzed HPLC 
purified peptides was performed using standard PITC precolumn 
derivatization protocols and analytical instrumentation (Applied 
Biosystems, Foster City, CA, USA). 
Protein sequence analysis of phosphopeptides was performed on a 
Milligen Model 6600 solid-phase sequenator (Milligen/Biosearch) us- 
ing standard protocols or an ABI Model 477 instrument (Applied 
Biosystems) using degradation cycles modified for the efficient ex- 
traction of P-eliminated phosphate [lo]. Peptides were covalently at- 
tached by water soluble carbodiimide to arylamine modified glass 
fibre membranes or arylamine modified polyvinylidene difluoride 
membranes (Sequelon AA, Milligen/Biosearch) as described [11,121. 
The site of phosphorylation was determined by correlating the PTH 
signal with P-eliminated [3ZP]phosphate in a given cycle. 
3. RESULTS 
MBP was cleaved with trypsin following in vitro 
phosphorylation of the protein to a stoichiometry of 0.8 
mol P/mol MBP by purified ~44~~~ with [y-“P]ATP. 
HPLC analysis of tryptic peptides from MBP revealed 
the presence of at least three partially resolved peptide 
peaks (nos 7, 8 and 9) that contained radio-label (Fig. 
224 
1A). The early elution (12-13’70 acetonitrile) of these 
peptides from the C4 reverse phase column implied that 
they were relatively hydrophilic. Autoradiography 
following two-dimensional separation of the phospho- 
peptides in HPLC peaks nos 7,8 and 9 showed an iden- 
tical pattern of one dominant phosphopeptide (data not 
shown). The appearance of the same major spot on 
autoradiograms of phosphopeptide maps was also seen 
when the unfractionated preparation of trypsinized 
radio-labelled MBP was subjected to the same pro- 
cedure (Fig. 2). 
To establish the nature of the amino acid residue in 
MBP that was phosphorylated by ~44”~~, a small 
amount of the phosphopeptide collected from HPLC 
(peak no. 8) was hydrolyzed with 6 M HCI. The 
resulting phosphoamino acids were analyzed by elec- 
trophoresis on silica TLC plates (Fig. 3). Over 90% of 
the phosphorus was incorporated on threonine. There 
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Fig. 1. HPLC profile of tryptic peptides derived from ~44”~‘- 
phosphorylated MBP. (A) The peptides were resolved on a C-4 
reverse phase column (unbroken line) and the corresponding radioac- 
tivity in each fraction was quantitated by liquid scintillation counting 
(0). The recovery of radio-label in the major peptide peaks was 38%. 
(B) Peak no. 7 from panel A was rechromatographed on a C-18 
reverse phase column. The radioactivity in peak nos 1, 2, 3 and 4 was 
145, 345, 225 and 4650, respectively. The recovery of radio-label in 
peak no. 4 was 38%. (C) Peak no. 8 from panel A was 
rechromatographed on a C-18 reverse phase column. The radioactivi- 
ty in peak nos 1, 2 and 3, was 615, 1235, and 9935, respectively. The 
recovery of radiolabel in peak no. 3 was 28%. The peptide peaks were 
monitored at wavelengths 215 and 280 nm, but only the data from 215 
nm is shown (unbroken line). 
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Fig. 2. Autoradiogram of two-dimensional map of tryptic 
phosphopeptides derived from MBP phosphorylated in vitro by 
~44~~‘. MBP (50 fig) was incubated with ~44~” (0.1 gg) in the 
presence of [Y-~*P]ATP, and subsequently tryptic phosphopeptid~ 
were prepared and subjected to electrophoresis and TLC as described 
in section 2. 
was little serine phosphoryIation. No tyrosine 
phosphorylation was detected. 
Amino acid composition analysis of the phosphopep- 
tide containing the site phosphorylated by ~44~~~ 
revealed that it had a high proline content (data not 
shown). As judged by the cleavage specificity of trypsin 
for peptide bonds C-terminal to basic amino acids, only 
a peptide spanning residues 91-104 of MBP featured 
the determined amino acid composition. This 
prelimi~y assignment of this peptide as contai~ng the 
in vitro phosphorylation site of MBP by ~44~~~ was 
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Fig. 3. Phosphoamino acid analysis of MBP phosphorylated by 
p44@ , HPLC peak no. 8 from phosphorylated and trypsinized MBP 
was hydrolyzed with constant boiling HCI and subjected to 
phosphoamino acid analysis as described in section 2. The 
phosphoamino acid standards were visualized with ninhydrin and 
their migration ~sitions are indicated on the autoradio~~. 
Table I 
Sequence of radio-labelled tryptic peptide from ~44’“~~ phosphorylated MBP 
Cycle Deduced Position Radioactivity (cpm) 
amino acid Peak (no. 7) Peak (no. 8) 
1 Asn 91 20 126 
2 Ile 92 10 43 
3 Val 93 11 25 
4 Thr 94 29 16 
5 Pro 95 12 I4 
6 Arg 96 10 13 
7 Thr 97 63 108 
8 Pro 98 25 26 
9 Pro 99 19 17 
10 Pro 100 18 23 
11 Ser 101 17 12 
12 Gln 102 13 9 
13 GlY 103 12 21 
14 Lys 104 12 18 
The radio-labelled peptides in HPLC peaks (no. 7) and (no. 8) were further separated from 
co-eluting, non-radio-labelled peptides by HPLC, and then sequenced using solid-phase Ed- 
man degradation. The deduced amino acid residue and the amount of radioactivity released 
in each cycle is shown. Cycle 1 radioa~ivity arose from the removal of [3zP]phosphate by fi- 
elimination during sequencing. 
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confirmed by subjecting peptides contained in HPLC 
peak no. 8 to peptide sequence analysis. 
Rechromatography of peak no. 8 using different 
separation conditions indicated that it contained 3 dif- 
ferent peptide species (Fig. 1C). The major protein 
peak, which contained most of the 32P-label, cor- 
responded to peptides 91-104. The determined se- 
quence of this phosphopeptide is shown in Table I. 
The phosphopeptide contained threonine residues at 
positions 94 and 97. Therefore, it was import~t to 
establish the sites phosphoryIated by ~44’“~~. Quantita- 
tion of the radioactivity (@-eliminated phosphate) ex- 
tracted with each cycle during solid-phase Edman 
degradation of the phosphopeptide demonstrated that 
Thr-97 was the major site of phosphorylation (Table I). 
A minor fraction of phosphopeptide, mainly eluting in 
peak no. 7 from the first HPLC column (Fig. 1A) and 
peak no. 4 from the second HPLC column (Fig. lB), 
contained a smaller amount of 32P-label incorporated 
into Thr-94, in addition to Thr-97, 
4. DISCUSSION 
Thr-97 and Thr-94 of MBP represent he first ~44~~~ 
phosphorylation sites that have been identified. Protein 
kinase C has been shown to initially phosphorylate 
Ser-114 in the corrected bovine MBP primary sequence 
[13]. However, a synthetic peptide patterned after 
residues 96-106 of MBP was not phosphorylated by 
protein kinase C 1131. The presence of proline residues 
surrounding Thr-97 may participate in recognition of 
this site by p44”pk. The cdc-2-encoded protein kinase 
appears to phospho~late serine and threonine residues 
that are bordered by a proline on the C-terminal side of 
the phosphorylation site [14], although this has yet to be 
established with synthetic peptide substrates. However, 
preliminary studies with synthetic peptide substrates of 
p44mpk imply that a proline residue on the N-terminal 
side of the phosphorylated amino acid may be a positive 
determinant for recognition by this protein kinase (I. 
Clark-Lewis, J.S. and S.P., unpublished data). Addi- 
tional peptides modelled after the ~44~~’ phosphoryla- 
tion site in MBP should permit a clearer definition of 
thecritical residues involved in substrate recognition by 
the protein kinase. Such phosphorylation site sequence 
information will be valuable for the identification of 
physiological targets of ~44~~~ and related homologs. 
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